tiprankstipranks
Viemed Healthcare US (VMD)
NASDAQ:VMD
US Market
Want to see VMD full AI Analyst Report?

Viemed Healthcare (VMD) Earnings Dates, Call Summary & Reports

177 Followers

Earnings Data

Report Date
Aug 12, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.12
Last Year’s EPS
0.08
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 05, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented strong operational and financial progress: revenue growth of 28% YoY, substantial free cash flow improvement, meaningful scaling in sleep (PAP up 57% YoY) and maternal health expansion, improved capital efficiency and a stronger, more diversified revenue mix. Near-term headwinds are largely related to NCD-driven compliance effects in ventilation (higher turnover and temporary pressure on net census), some seasonality, and comparability issues from a prior-year gain. Management reiterated positive guidance, tightened revenue guidance upward, and highlighted continued margin and cash-flow improvement, indicating confidence in execution.
Company Guidance
Management updated full‑year guidance to net revenue of $312–$320 million (raised the low end from $310M), reaffirmed adjusted EBITDA of $65–$69 million (implying a full‑year adjusted EBITDA margin of roughly 21%–22%), and narrowed net CapEx to 9.0%–10.5% of net revenue (from 10%–11.5%), while forecasting sequential revenue growth of about 3%–5% per quarter through the remainder of 2026. Those targets are anchored by Q1 results of $75.4 million revenue (up 28% YoY), Q1 adjusted EBITDA of $14.3 million (19% margin), Q1 free cash flow of $2.6 million (vs. -$5.7M prior, an $8.3M improvement), trailing‑12‑month FCF of $36.3M, Q1 net CapEx ≈7.3% of revenue, cash of $9.8M with $46M available on the credit facility, 150,000 shares repurchased for $1.4M, and long‑term debt reduced to $8.3M.
Revenue Growth
Q1 revenue of $75.4 million, up 28% year-over-year and essentially flat sequentially vs Q4 2025 ($76.2M), consistent with expected seasonality.
Strong Free Cash Flow Improvement
Free cash flow of $2.6 million vs negative $5.7 million in prior year, an $8.3 million improvement; trailing twelve-month free cash flow increased to $36.3 million (from $23.3M through 2025 and $11.6M at end of 2024).
Sleep Business Momentum
PAP therapy patient count reached 35,938 (nearly 36,000), up 57% year-over-year and 4% sequentially; resupply patients up 47% year-over-year, driving recurring, predictable revenue.
Maternal Health Expansion and Integration
Lehan integration accretive since acquisition; serviced just under 4,000 new maternal health patients in markets where Lehan previously had no presence, demonstrating scalable platform leverage.
Diversifying Revenue Mix
Ventilator rentals were $35.4M (approx. 47% of revenue) vs 54% in 2025; other HME rentals $16.2M (+25% YoY); equipment & supply sales $17.5M, more than doubling from $7.5M, reducing concentration risk and improving capital efficiency.
Profitability and Margin Progress
Gross profit $42.8M with gross margin of 56.8% (vs 56.3% prior year); adjusted EBITDA $14.3M (19% of revenue). On a comparable basis (excluding a prior-year $2.7M gain), adjusted EBITDA margin expanded ~200 basis points year-over-year.
Operating Cash Flow & CapEx Efficiency
Operating cash flow $8.1M vs $2.9M prior year (nearly 3x); net CapEx $5.5M vs $8.5M prior year; updated full-year net CapEx outlook to 9.0%–10.5% of net revenue (from prior 10%–11.5%).
Strong Balance Sheet & Capital Returns
Ended quarter with $9.8M cash, $46M available credit, long-term debt reduced to $8.3M; repurchased and canceled 150,000 shares for $1.4M and made $3.2M principal debt payments.
Positive Operational Signals in Ventilation
New ventilator setup momentum ahead of expectations: March starts 759 vs 692 a year ago (+~9.7%); compliance among active ventilator patients improved nearly 20% since NCD implementation.
Guidance Update and Confidence
Raised low end of full-year net revenue guidance to $312M–$320M (from $310M–$320M) and reaffirmed adjusted EBITDA guidance of $65M–$69M; expect sequential revenue growth of ~3%–5% per quarter through year.

Viemed Healthcare (VMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

VMD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 12, 2026
2026 (Q2)
0.12 / -
0.08
May 05, 2026
2026 (Q1)
0.09 / 0.06
0.060.00% (0.00)
Mar 04, 2026
2025 (Q4)
0.13 / 0.14
0.140.00% (+0.04)
Nov 05, 2025
2025 (Q3)
0.09 / 0.09
0.1-10.00% (-0.01)
Nov 05, 2025
2026 (Q1)
0.09 / 0.06
0.060.00% (0.00)
Aug 06, 2025
2025 (Q2)
0.09 / 0.08
0.04100.00% (+0.04)
May 07, 2025
2025 (Q1)
0.06 / 0.06
0.0450.00% (+0.02)
Mar 10, 2025
2024 (Q4)
0.10 / 0.10
0.0911.11% (+0.01)
Nov 06, 2024
2024 (Q3)
0.07 / 0.10
0.0742.86% (+0.03)
Aug 07, 2024
2024 (Q2)
0.07 / 0.04
0.06-33.33% (-0.02)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

VMD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 05, 2026
$9.70$8.52-12.22%
Mar 04, 2026
$9.08$8.40-7.49%
Nov 05, 2025
$6.43$6.26-2.64%
Nov 05, 2025
$6.43$6.26-2.64%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Viemed Healthcare US (VMD) report earnings?
Viemed Healthcare US (VMD) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
    What is Viemed Healthcare US (VMD) earnings time?
    Viemed Healthcare US (VMD) earnings time is at Aug 12, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is VMD EPS forecast?
          VMD EPS forecast for the fiscal quarter 2026 (Q2) is 0.12.

            Viemed Healthcare (VMD) Earnings News

            Viemed Healthcare Stock Finishes 14.2% Lower on Earnings Miss
            Premium
            Market News
            Viemed Healthcare Stock Finishes 14.2% Lower on Earnings Miss
            4y ago